[1]
Frantellizzi, V.; Lavelli, V.; Ferrari, C.; Sardaro, A.; Farcomeni, A.; Pacilio, M.; Borrazzo, C.; Pani, R.; Rubini, G.; Vincentis, G. Diagnostic value of the early heart-to-mediastinum count ratio in cardiac 123i-mibg imaging for parkinson’s disease. Curr. Radiopharm., 2021, 14(1), 64-69.
[http://dx.doi.org/10.2174/1874471013999200727211633] [PMID: 32720610]
[http://dx.doi.org/10.2174/1874471013999200727211633] [PMID: 32720610]
[2]
Maruyama, Y.; Yamada, T.; Murakami, K.; Kumano, R. Comparison of the diagnostic performance of H/M ratio between early and delayed phases for Lewy body disease. Nucl. Med. Commun., 2015, 36(5), 477-480.
[http://dx.doi.org/10.1097/MNM.0000000000000271] [PMID: 25714666]
[http://dx.doi.org/10.1097/MNM.0000000000000271] [PMID: 25714666]
[3]
Nuvoli, S.; Spanu, A.; Fravolini, M.L.; Bianconi, F.; Cascianelli, S.; Madeddu, G.; Palumbo, B. [123I]Metaiodobenzylguanidine (MIBG) cardiac scintigraphy and automated classification techniques in parkinsonian disorders. Mol. Imaging Biol., 2020, 22(3), 703-710.
[http://dx.doi.org/10.1007/s11307-019-01406-6] [PMID: 31309370]
[http://dx.doi.org/10.1007/s11307-019-01406-6] [PMID: 31309370]
[4]
Ricci, M.; Cimini, A.; Chiaravalloti, A.; Filippi, L.; Schillaci, O. Positron emission tomography (PET) and neuroimaging in the personalized approach to neurodegenerative causes of dementia. Int. J. Mol. Sci., 2020, 21(20), 7481.
[http://dx.doi.org/10.3390/ijms21207481] [PMID: 33050556]
[http://dx.doi.org/10.3390/ijms21207481] [PMID: 33050556]
[5]
Xu, D.; Zhu, W.; Huo, L.; Zhu, S.; Li, F.; Wang, H. Validation of Iodine-131-meta-iodobenzylguanidine cardiac scintigraphy in Parkinsonism: A preliminary study. Parkinsonism Relat. Disord., 2018, 50, 69-73.
[http://dx.doi.org/10.1016/j.parkreldis.2018.02.020] [PMID: 29475590]
[http://dx.doi.org/10.1016/j.parkreldis.2018.02.020] [PMID: 29475590]
[6]
Nuvoli, S.; Palumbo, B.; Malaspina, S.; Madeddu, G.; Spanu, A. 123I-ioflupane SPET and 123I-MIBG in the diagnosis of Parkinson’s disease and parkinsonian disorders and in the differential diagnosis between Alzheimer’s and Lewy’s bodies dementias. Hell. J. Nucl. Med., 2018, 21(1), 60-68.
[PMID: 29550847]
[PMID: 29550847]
[7]
Agostini, D.; Verberne, H.J.; Hamon, M.; Jacobson, A.F.; Manrique, A. Cardiac 123I-MIBG scintigraphy in heart failure. Q. J. Nucl. Med. Mol. Imaging, 2008, 52(4), 369-377.
[PMID: 19088691]
[PMID: 19088691]
[8]
Teresińska, A. I-123-MIBG cardiac innervation imaging in patients with atrial fibrillation. J. Nucl. Cardiol., 2020, 27(6), 1951-1954.
[http://dx.doi.org/10.1007/s12350-019-01601-6] [PMID: 30694426]
[http://dx.doi.org/10.1007/s12350-019-01601-6] [PMID: 30694426]
[9]
Orimo, S.; Suzuki, M.; Inaba, A.; Mizusawa, H. 123I-MIBG myocardial scintigraphy for differentiating Parkinson’s disease from other neurodegenerative parkinsonism: A systematic review and meta-analysis. Parkinsonism Relat. Disord., 2012, 18(5), 494-500.
[http://dx.doi.org/10.1016/j.parkreldis.2012.01.009] [PMID: 22321865]
[http://dx.doi.org/10.1016/j.parkreldis.2012.01.009] [PMID: 22321865]
Related Books
Frontiers in Clinical Drug Research - Anti-Cancer Agents
The Management of Metastatic Triple-Negative Breast Cancer: An Integrated and Expeditionary Approach
Cancer Genes
Cancer Medicine in an Ayurvedic Perspective: A Critical Overview
Cancer Genes
Anticancer Immunity: Reviewing the Potential of Probiotics
Probiotics in Anticancer Immunity
Phytonutrients in the Treatment of Gastrointestinal Cancer
Molecular Targets and Cancer Therapeutics (Part 2)
Molecular Targets and Cancer Therapeutics (Part 1)
Article Metrics
32
2